Total Funding
53
54
Total FundingPost-IPO Equity raised
Growth Score 53 in past quarter
-18 pts
Heat Score 54 in past quarter
-28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
137714
Klotho Neurosciences develops disease modifying therapies for age-related cognitive and neurodegenerative disorders and cancer.
- Jeffrey LeBlanc: CFOPast Role: Out of Print, Co-Founder
- Peter Moriarty: COOPast Role: Prismic Pharmaceuticals, Chairman and CEO
About the Company
Klotho Neurosciences develops and provide disruptive new therapies to alleviate and/or reverse the progression of cancer and neurodegenerative diseases through the use of cell and gene therapy